Broadview Ventures is a venture capital firm focused on accelerating the development of promising technologies for cardiovascular disease and stroke. They invest in early-stage companies developing innovative solutions for diagnosis and treatment in the cardiovascular and neurovascular spaces. Their typical investments range from seed to Series A rounds, with occasional participation in later stages.
The firm's portfolio includes a diverse range of companies such as Aria CV, AtaCor Medical, and Lyra Therapeutics. Broadview Ventures emphasizes impact investing, aiming to bring new treatments to patients through targeted investments. Their approach combines financial support with strategic guidance to help portfolio companies advance their technologies and reach clinical milestones.
Broadview Ventures - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments33
Current Portfolio Count26
Total Portfolio Exits2
Top Investment Stages
Series A12 (38.7%)
Debt Financing8 (25.8%)
Seed6 (19.4%)
Series B3 (9.7%)
Series Unknown2 (6.5%)
Stage Mix
Series A 39%Debt Financing 26%Seed 19%Series B 10%Series Unknown 6%
Concentration shown as share of disclosed investments by stage.
Broadview Ventures - Classification
- Also Known As
- Broadview Ventures, Inc.
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- 523940Portfolio Management and Investment Advice
- SIC
- 6000Depository Institutions
- 6720Investment Offices
- 6722Management Investment Offices, Open-end